NCT01707849View on ClinicalTrials.gov

The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation

PHASE3CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Hepatitis C Recurrence After Liver Transplant
Interventions
DRUG

EVL arm

Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.

DRUG

MMF arm

Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.

Trial Locations (1)

08035

Department of HPB Surgery and Transplant, Hospital Vall d´Hebron, Barcelona

All Listed Sponsors
lead

Hospital Vall d'Hebron

OTHER

NCT01707849 - The Impact of Everolimus Based Immunosuppression in the Evolution of Hepatitis C Fibrosis After Liver Transplantation | Biotech Hunter | Biotech Hunter